Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy
Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy. Elevated levels of NH2-terminal truncated CXCL10 (3-77aa), produced by DPP4 cleavage, negatively associate with spontaneous clearance of acute...
Saved in:
| Published in | PloS one Vol. 10; no. 7; p. e0133236 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
16.07.2015
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0133236 |
Cover
Loading…
| Abstract | Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy. Elevated levels of NH2-terminal truncated CXCL10 (3-77aa), produced by DPP4 cleavage, negatively associate with spontaneous clearance of acute HCV infection and sustained virological response (SVR) with IFN-based therapy for chronic infection. The association of different CXCL10 forms and DPP4 with outcome during IFN-free HCV therapy has not been examined. Using novel Simoa assays, plasma was analyzed from HCV genotype-1 (GT1) subjects who relapsed (n = 11) or achieved SVR (n = 10) after sofosbuvir and ribavirin (SOF/RBV) treatment, and from SOF/RBV relapsers who achieved SVR with a subsequent SOF/ledipasvir regimen (n = 9). While the NH2-truncated form of CXCL10 was elevated in HCV infection relative to healthy controls, pre-treatment plasma concentrations of CXCL10 forms failed to stratify subjects based on treatment outcome to IFN-free regimens. However, a trend (statistically non-significant) towards elevated higher levels of total and long CXCL10 was observed pre-treatment in subjects who relapsed. All forms of CXCL10 decreased rapidly following treatment initiation and were again elevated in subjects who experienced HCV relapse, indicating that CXCL10 production may be associated with active viral replication. While soluble DPP4 (sDPP4) and NH2-truncated CXCL10 concentrations were highly correlated, on-treatment sDPP4 levels and activity declined more slowly than CXCL10, suggesting differential regulation. These data suggest post-translationally modified forms of CXCL10 will not support the prediction of treatment outcome in HCV GT1 subjects treated with SOF/RBV. |
|---|---|
| AbstractList | Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy. Elevated levels of NH2-terminal truncated CXCL10 (3-77aa), produced by DPP4 cleavage, negatively associate with spontaneous clearance of acute HCV infection and sustained virological response (SVR) with IFN-based therapy for chronic infection. The association of different CXCL10 forms and DPP4 with outcome during IFN-free HCV therapy has not been examined. Using novel Simoa assays, plasma was analyzed from HCV genotype-1 (GT1) subjects who relapsed (n = 11) or achieved SVR (n = 10) after sofosbuvir and ribavirin (SOF/RBV) treatment, and from SOF/RBV relapsers who achieved SVR with a subsequent SOF/ledipasvir regimen (n = 9). While the NH2-truncated form of CXCL10 was elevated in HCV infection relative to healthy controls, pre-treatment plasma concentrations of CXCL10 forms failed to stratify subjects based on treatment outcome to IFN-free regimens. However, a trend (statistically non-significant) towards elevated higher levels of total and long CXCL10 was observed pre-treatment in subjects who relapsed. All forms of CXCL10 decreased rapidly following treatment initiation and were again elevated in subjects who experienced HCV relapse, indicating that CXCL10 production may be associated with active viral replication. While soluble DPP4 (sDPP4) and NH2-truncated CXCL10 concentrations were highly correlated, on-treatment sDPP4 levels and activity declined more slowly than CXCL10, suggesting differential regulation. Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy. Elevated levels of NH2-terminal truncated CXCL10 (3-77aa), produced by DPP4 cleavage, negatively associate with spontaneous clearance of acute HCV infection and sustained virological response (SVR) with IFN-based therapy for chronic infection. The association of different CXCL10 forms and DPP4 with outcome during IFN-free HCV therapy has not been examined. Using novel Simoa assays, plasma was analyzed from HCV genotype-1 (GT1) subjects who relapsed (n = 11) or achieved SVR (n = 10) after sofosbuvir and ribavirin (SOF/RBV) treatment, and from SOF/RBV relapsers who achieved SVR with a subsequent SOF/ledipasvir regimen (n = 9). While the NH2-truncated form of CXCL10 was elevated in HCV infection relative to healthy controls, pre-treatment plasma concentrations of CXCL10 forms failed to stratify subjects based on treatment outcome to IFN-free regimens. However, a trend (statistically non-significant) towards elevated higher levels of total and long CXCL10 was observed pre-treatment in subjects who relapsed. All forms of CXCL10 decreased rapidly following treatment initiation and were again elevated in subjects who experienced HCV relapse, indicating that CXCL10 production may be associated with active viral replication. While soluble DPP4 (sDPP4) and NH2-truncated CXCL10 concentrations were highly correlated, on-treatment sDPP4 levels and activity declined more slowly than CXCL10, suggesting differential regulation. Conclusion These data suggest post-translationally modified forms of CXCL10 will not support the prediction of treatment outcome in HCV GT1 subjects treated with SOF/RBV. Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy. Elevated levels of NH2-terminal truncated CXCL10 (3-77aa), produced by DPP4 cleavage, negatively associate with spontaneous clearance of acute HCV infection and sustained virological response (SVR) with IFN-based therapy for chronic infection. The association of different CXCL10 forms and DPP4 with outcome during IFN-free HCV therapy has not been examined. Using novel Simoa assays, plasma was analyzed from HCV genotype-1 (GT1) subjects who relapsed (n = 11) or achieved SVR (n = 10) after sofosbuvir and ribavirin (SOF/RBV) treatment, and from SOF/RBV relapsers who achieved SVR with a subsequent SOF/ledipasvir regimen (n = 9). While the NH2-truncated form of CXCL10 was elevated in HCV infection relative to healthy controls, pre-treatment plasma concentrations of CXCL10 forms failed to stratify subjects based on treatment outcome to IFN-free regimens. However, a trend (statistically non-significant) towards elevated higher levels of total and long CXCL10 was observed pre-treatment in subjects who relapsed. All forms of CXCL10 decreased rapidly following treatment initiation and were again elevated in subjects who experienced HCV relapse, indicating that CXCL10 production may be associated with active viral replication. While soluble DPP4 (sDPP4) and NH.sub.2 -truncated CXCL10 concentrations were highly correlated, on-treatment sDPP4 levels and activity declined more slowly than CXCL10, suggesting differential regulation. Conclusion These data suggest post-translationally modified forms of CXCL10 will not support the prediction of treatment outcome in HCV GT1 subjects treated with SOF/RBV. Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy. Elevated levels of NH2-terminal truncated CXCL10 (3-77aa), produced by DPP4 cleavage, negatively associate with spontaneous clearance of acute HCV infection and sustained virological response (SVR) with IFN-based therapy for chronic infection. The association of different CXCL10 forms and DPP4 with outcome during IFN-free HCV therapy has not been examined. Using novel Simoa assays, plasma was analyzed from HCV genotype-1 (GT1) subjects who relapsed (n = 11) or achieved SVR (n = 10) after sofosbuvir and ribavirin (SOF/RBV) treatment, and from SOF/RBV relapsers who achieved SVR with a subsequent SOF/ledipasvir regimen (n = 9). While the NH2-truncated form of CXCL10 was elevated in HCV infection relative to healthy controls, pre-treatment plasma concentrations of CXCL10 forms failed to stratify subjects based on treatment outcome to IFN-free regimens. However, a trend (statistically non-significant) towards elevated higher levels of total and long CXCL10 was observed pre-treatment in subjects who relapsed. All forms of CXCL10 decreased rapidly following treatment initiation and were again elevated in subjects who experienced HCV relapse, indicating that CXCL10 production may be associated with active viral replication. While soluble DPP4 (sDPP4) and NH.sub.2 -truncated CXCL10 concentrations were highly correlated, on-treatment sDPP4 levels and activity declined more slowly than CXCL10, suggesting differential regulation. These data suggest post-translationally modified forms of CXCL10 will not support the prediction of treatment outcome in HCV GT1 subjects treated with SOF/RBV. Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy. Elevated levels of NH2-terminal truncated CXCL10 (3-77aa), produced by DPP4 cleavage, negatively associate with spontaneous clearance of acute HCV infection and sustained virological response (SVR) with IFN-based therapy for chronic infection. The association of different CXCL10 forms and DPP4 with outcome during IFN-free HCV therapy has not been examined. Using novel Simoa assays, plasma was analyzed from HCV genotype-1 (GT1) subjects who relapsed (n = 11) or achieved SVR (n = 10) after sofosbuvir and ribavirin (SOF/RBV) treatment, and from SOF/RBV relapsers who achieved SVR with a subsequent SOF/ledipasvir regimen (n = 9). While the NH2-truncated form of CXCL10 was elevated in HCV infection relative to healthy controls, pre-treatment plasma concentrations of CXCL10 forms failed to stratify subjects based on treatment outcome to IFN-free regimens. However, a trend (statistically non-significant) towards elevated higher levels of total and long CXCL10 was observed pre-treatment in subjects who relapsed. All forms of CXCL10 decreased rapidly following treatment initiation and were again elevated in subjects who experienced HCV relapse, indicating that CXCL10 production may be associated with active viral replication. While soluble DPP4 (sDPP4) and NH2-truncated CXCL10 concentrations were highly correlated, on-treatment sDPP4 levels and activity declined more slowly than CXCL10, suggesting differential regulation. These data suggest post-translationally modified forms of CXCL10 will not support the prediction of treatment outcome in HCV GT1 subjects treated with SOF/RBV. Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy. Elevated levels of NH2-terminal truncated CXCL10 (3-77aa), produced by DPP4 cleavage, negatively associate with spontaneous clearance of acute HCV infection and sustained virological response (SVR) with IFN-based therapy for chronic infection. The association of different CXCL10 forms and DPP4 with outcome during IFN-free HCV therapy has not been examined. Using novel Simoa assays, plasma was analyzed from HCV genotype-1 (GT1) subjects who relapsed (n = 11) or achieved SVR (n = 10) after sofosbuvir and ribavirin (SOF/RBV) treatment, and from SOF/RBV relapsers who achieved SVR with a subsequent SOF/ledipasvir regimen (n = 9). While the NH2-truncated form of CXCL10 was elevated in HCV infection relative to healthy controls, pre-treatment plasma concentrations of CXCL10 forms failed to stratify subjects based on treatment outcome to IFN-free regimens. However, a trend (statistically non-significant) towards elevated higher levels of total and long CXCL10 was observed pre-treatment in subjects who relapsed. All forms of CXCL10 decreased rapidly following treatment initiation and were again elevated in subjects who experienced HCV relapse, indicating that CXCL10 production may be associated with active viral replication. While soluble DPP4 (sDPP4) and NH2-truncated CXCL10 concentrations were highly correlated, on-treatment sDPP4 levels and activity declined more slowly than CXCL10, suggesting differential regulation. Conclusion These data suggest post-translationally modified forms of CXCL10 will not support the prediction of treatment outcome in HCV GT1 subjects treated with SOF/RBV. Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy. Elevated levels of NH2-terminal truncated CXCL10 (3-77aa), produced by DPP4 cleavage, negatively associate with spontaneous clearance of acute HCV infection and sustained virological response (SVR) with IFN-based therapy for chronic infection. The association of different CXCL10 forms and DPP4 with outcome during IFN-free HCV therapy has not been examined. Using novel Simoa assays, plasma was analyzed from HCV genotype-1 (GT1) subjects who relapsed (n = 11) or achieved SVR (n = 10) after sofosbuvir and ribavirin (SOF/RBV) treatment, and from SOF/RBV relapsers who achieved SVR with a subsequent SOF/ledipasvir regimen (n = 9). While the NH2-truncated form of CXCL10 was elevated in HCV infection relative to healthy controls, pre-treatment plasma concentrations of CXCL10 forms failed to stratify subjects based on treatment outcome to IFN-free regimens. However, a trend (statistically non-significant) towards elevated higher levels of total and long CXCL10 was observed pre-treatment in subjects who relapsed. All forms of CXCL10 decreased rapidly following treatment initiation and were again elevated in subjects who experienced HCV relapse, indicating that CXCL10 production may be associated with active viral replication. While soluble DPP4 (sDPP4) and NH 2 -truncated CXCL10 concentrations were highly correlated, on-treatment sDPP4 levels and activity declined more slowly than CXCL10, suggesting differential regulation. Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy. Elevated levels of NH2-terminal truncated CXCL10 (3-77aa), produced by DPP4 cleavage, negatively associate with spontaneous clearance of acute HCV infection and sustained virological response (SVR) with IFN-based therapy for chronic infection. The association of different CXCL10 forms and DPP4 with outcome during IFN-free HCV therapy has not been examined. Using novel Simoa assays, plasma was analyzed from HCV genotype-1 (GT1) subjects who relapsed (n = 11) or achieved SVR (n = 10) after sofosbuvir and ribavirin (SOF/RBV) treatment, and from SOF/RBV relapsers who achieved SVR with a subsequent SOF/ledipasvir regimen (n = 9). While the NH2-truncated form of CXCL10 was elevated in HCV infection relative to healthy controls, pre-treatment plasma concentrations of CXCL10 forms failed to stratify subjects based on treatment outcome to IFN-free regimens. However, a trend (statistically non-significant) towards elevated higher levels of total and long CXCL10 was observed pre-treatment in subjects who relapsed. All forms of CXCL10 decreased rapidly following treatment initiation and were again elevated in subjects who experienced HCV relapse, indicating that CXCL10 production may be associated with active viral replication. While soluble DPP4 (sDPP4) and NH2-truncated CXCL10 concentrations were highly correlated, on-treatment sDPP4 levels and activity declined more slowly than CXCL10, suggesting differential regulation. These data suggest post-translationally modified forms of CXCL10 will not support the prediction of treatment outcome in HCV GT1 subjects treated with SOF/RBV.Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy. Elevated levels of NH2-terminal truncated CXCL10 (3-77aa), produced by DPP4 cleavage, negatively associate with spontaneous clearance of acute HCV infection and sustained virological response (SVR) with IFN-based therapy for chronic infection. The association of different CXCL10 forms and DPP4 with outcome during IFN-free HCV therapy has not been examined. Using novel Simoa assays, plasma was analyzed from HCV genotype-1 (GT1) subjects who relapsed (n = 11) or achieved SVR (n = 10) after sofosbuvir and ribavirin (SOF/RBV) treatment, and from SOF/RBV relapsers who achieved SVR with a subsequent SOF/ledipasvir regimen (n = 9). While the NH2-truncated form of CXCL10 was elevated in HCV infection relative to healthy controls, pre-treatment plasma concentrations of CXCL10 forms failed to stratify subjects based on treatment outcome to IFN-free regimens. However, a trend (statistically non-significant) towards elevated higher levels of total and long CXCL10 was observed pre-treatment in subjects who relapsed. All forms of CXCL10 decreased rapidly following treatment initiation and were again elevated in subjects who experienced HCV relapse, indicating that CXCL10 production may be associated with active viral replication. While soluble DPP4 (sDPP4) and NH2-truncated CXCL10 concentrations were highly correlated, on-treatment sDPP4 levels and activity declined more slowly than CXCL10, suggesting differential regulation. These data suggest post-translationally modified forms of CXCL10 will not support the prediction of treatment outcome in HCV GT1 subjects treated with SOF/RBV. |
| Audience | Academic |
| Author | Casrouge, Armanda Duffy, Darragh Decalf, Jérémie Meissner, Eric G. Kottilil, Shyam Albert, Matthew L. Masur, Henry |
| AuthorAffiliation | 2 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, United States of America 5 INSERM U818, Paris, France 1 Division of Infectious Diseases, Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States of America University of Washington, UNITED STATES 3 Critical Care Medicine Department, NIH, Bethesda, MD, United States of America 7 Center for Human Immunology, Institut Pasteur, Paris, France 6 Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States of America 4 The Laboratory of Dendritic Cell Immunobiology, Institut Pasteur, Paris, France |
| AuthorAffiliation_xml | – name: 3 Critical Care Medicine Department, NIH, Bethesda, MD, United States of America – name: 2 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, United States of America – name: 4 The Laboratory of Dendritic Cell Immunobiology, Institut Pasteur, Paris, France – name: 6 Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States of America – name: University of Washington, UNITED STATES – name: 7 Center for Human Immunology, Institut Pasteur, Paris, France – name: 5 INSERM U818, Paris, France – name: 1 Division of Infectious Diseases, Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States of America |
| Author_xml | – sequence: 1 givenname: Eric G. surname: Meissner fullname: Meissner, Eric G. – sequence: 2 givenname: Jérémie surname: Decalf fullname: Decalf, Jérémie – sequence: 3 givenname: Armanda surname: Casrouge fullname: Casrouge, Armanda – sequence: 4 givenname: Henry surname: Masur fullname: Masur, Henry – sequence: 5 givenname: Shyam surname: Kottilil fullname: Kottilil, Shyam – sequence: 6 givenname: Matthew L. surname: Albert fullname: Albert, Matthew L. – sequence: 7 givenname: Darragh surname: Duffy fullname: Duffy, Darragh |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26181438$$D View this record in MEDLINE/PubMed https://pasteur.hal.science/pasteur-01380964$$DView record in HAL |
| BookMark | eNqNk11v0zAUhiM0xD7gHyCwhITgIsUfiZNwgTR1jFUq2rSNiTvLcU5aV65d7GSi1_xx3I9N6zQhlIvEJ897jv36nMNkzzoLSfKa4AFhBfk0c7230gwWMTzAhDHK-LPkgFSMppxitvfgez85DGGGcc5Kzl8k-5STkmSsPEj-nCytnGuFhlNpJxCQa9GFC1167aUNRnbaxSJmib67RrcaGnTq_HyNDX8OxwQjaRt05UxfG0AnFxcZ0hadDW_QVV_PQHUBXYICfavtBI1sB74F72x66gHQ9RS8XCxfJs9baQK82r6Pkh-nX6-HZ-n4_NtoeDxOVcFwl0rZlJDTVgFvVVmCBCAVLmhTSmjqnBGialrXFSWspsDrGiSBLI9LILSgGTtK3m7yLowLYutfEIRXvCxznhWRGG2IxsmZWHg9l34pnNRiHXB-IqTvtDIgOIVcKUaKgrSZyosSt00LZZ1LnlfR95jry7ZaX8-hUWA7L81O0t0_Vk_FxN2KLMdZxlfbTTcJpo9kZ8djsZChg96LePElrnh2SyL_YVvQu189hE7MdVBgjLTg-vU5S1Zhtj7nu0fo025sqYmMB9a2dXGfapVUHGeUYswJZpEaPEHFp4HYV7E5Wx3jO4KPO4LIdPC7m8g-BDG6uvx_9vxml33_gJ2CNN00xMZctXDYBd88vJl7b--mIgLZBlDeheChvUcIFqvhu7NLrIZPbIcvyj4_kindrScoOqLNv8V_AbdPM54 |
| CitedBy_id | crossref_primary_10_1007_s00018_023_04715_w crossref_primary_10_1021_acssensors_6b00256 crossref_primary_10_1016_j_ijmm_2019_05_005 crossref_primary_10_1186_s12933_017_0553_3 crossref_primary_10_1172_jci_insight_154314 crossref_primary_10_1039_C8AY01271G crossref_primary_10_1016_j_clim_2017_05_019 crossref_primary_10_1021_acs_jproteome_0c00494 crossref_primary_10_1021_acs_analchem_0c01507 crossref_primary_10_1021_acs_analchem_8b01198 crossref_primary_10_1038_s41598_022_18354_x crossref_primary_10_1016_j_ajpath_2018_08_017 crossref_primary_10_1016_j_cyto_2018_02_026 crossref_primary_10_3389_fimmu_2017_01970 crossref_primary_10_1016_j_ijid_2018_09_001 crossref_primary_10_15252_emmm_201506145 crossref_primary_10_1039_C6LC01238H crossref_primary_10_1002_elan_201600183 crossref_primary_10_3233_HAB_190381 crossref_primary_10_1093_infdis_jiaa126 crossref_primary_10_1371_journal_pone_0208225 crossref_primary_10_1016_j_bios_2016_12_052 crossref_primary_10_1038_srep40404 crossref_primary_10_3389_fimmu_2018_01456 crossref_primary_10_1186_s12964_023_01453_1 crossref_primary_10_3390_ijms21207473 crossref_primary_10_1002_hep4_1074 crossref_primary_10_1002_jia2_25144 |
| Cites_doi | 10.1111/liv.12748 10.1172/JCI75938 10.1002/hep.27139 10.1111/liv.12423 10.1111/j.1365-2249.2011.04488.x 10.1016/j.jhep.2010.12.033 10.7326/M14-1211 10.1053/j.gastro.2011.09.039 10.1002/hep.22500 10.1016/j.cyto.2013.04.016 10.1001/jama.2013.109309 10.1002/hep.24056 10.1086/507307 10.1126/science.1257737 10.1002/hep.21407 10.1016/j.jhep.2013.06.001 10.1016/j.jhep.2014.05.043 10.1016/j.jhep.2007.04.009 10.1172/JCI40594 10.1111/jgh.12462 10.1038/nbt.1641 10.1136/gut.2005.074062 10.1111/j.1365-2893.2006.00838.x 10.1371/journal.pone.0056991 10.1001/jama.2014.7085 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2015 Public Library of Science This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”) Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Attribution |
| Copyright_xml | – notice: COPYRIGHT 2015 Public Library of Science – notice: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”) Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Attribution |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1371/journal.pone.0133236 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed In Context: Opposing Viewpoints In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection (ProQuest) ProQuest Central Essentials Biological Science Collection (ProQuest) ProQuest Central Technology Collection Natural Science Collection (ProQuest) Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection (ProQuest) Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection (ProQuest) ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological science database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection (ProQuest) Genetics Abstracts MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Agricultural Science Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Changes in CXCL10 Forms during IFN-Free HCV Therapy |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1696885647 oai_doaj_org_article_62e5cc31771f4c5780fdfe8b5a659932 PMC4504464 oai_HAL_pasteur_01380964v1 3745590091 A422006103 26181438 10_1371_journal_pone_0133236 |
| Genre | Research Support, N.I.H., Intramural Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Intramural NIH HHS |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM CGR CUY CVF ECM EIF IPNFZ NPM PJZUB PPXIY PQGLB RIG BBORY PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 1XC VOOES 5PM PUEGO AAPBV ABPTK N95 |
| ID | FETCH-LOGICAL-c730t-aad8e52fce6fc88eaee19072d8aedb5311cb2bb9213b2e6bbea1e45213e127243 |
| IEDL.DBID | 7X7 |
| ISSN | 1932-6203 |
| IngestDate | Sun May 07 16:28:16 EDT 2023 Wed Aug 27 01:31:43 EDT 2025 Thu Aug 21 17:30:40 EDT 2025 Fri May 09 12:25:00 EDT 2025 Mon Jul 21 10:42:32 EDT 2025 Fri Jul 25 10:21:28 EDT 2025 Tue Jun 17 21:45:15 EDT 2025 Tue Jun 10 20:48:09 EDT 2025 Fri Jun 27 04:47:37 EDT 2025 Fri Jun 27 04:15:47 EDT 2025 Thu May 22 20:56:49 EDT 2025 Mon Jul 21 06:06:31 EDT 2025 Tue Jul 01 00:21:32 EDT 2025 Thu Apr 24 23:08:02 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Statistical data Biomarkers Post translational modifications Hepatitis C virus Viral replication Chemokines Blood plasma Enzyme-linked immunoassays |
| Language | English |
| License | Attribution: http://creativecommons.org/licenses/by This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. Creative Commons CC0 public domain |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c730t-aad8e52fce6fc88eaee19072d8aedb5311cb2bb9213b2e6bbea1e45213e127243 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 PMCID: PMC4504464 Competing Interests: A Collective Research and Development Agreement (CRADA) between the NIH and Gilead Sciences supported the clinical trials from which patient samples were used for the described experiments. No funds from this CRADA were used for this bench-based research project. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. These authors also contributed equally to this work. Conceived and designed the experiments: EGM JD AC SK MLA DD. Performed the experiments: EGM JD AC. Analyzed the data: EGM JD AC MLA DD. Contributed reagents/materials/analysis tools: EGM SK HM MLA. Wrote the paper: EGM JD AC SK MLA DD HM. |
| ORCID | 0000-0002-8875-2308 |
| OpenAccessLink | https://www.proquest.com/docview/1696885647?pq-origsite=%requestingapplication% |
| PMID | 26181438 |
| PQID | 1696885647 |
| PQPubID | 1436336 |
| ParticipantIDs | plos_journals_1696885647 doaj_primary_oai_doaj_org_article_62e5cc31771f4c5780fdfe8b5a659932 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4504464 hal_primary_oai_HAL_pasteur_01380964v1 proquest_miscellaneous_1698390347 proquest_journals_1696885647 gale_infotracmisc_A422006103 gale_infotracacademiconefile_A422006103 gale_incontextgauss_ISR_A422006103 gale_incontextgauss_IOV_A422006103 gale_healthsolutions_A422006103 pubmed_primary_26181438 crossref_primary_10_1371_journal_pone_0133236 crossref_citationtrail_10_1371_journal_pone_0133236 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2015-07-16 |
| PublicationDateYYYYMMDD | 2015-07-16 |
| PublicationDate_xml | – month: 07 year: 2015 text: 2015-07-16 day: 16 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2015 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | R Schinazi (ref1) 2014; 34 A Hill (ref6) 2014; 345 JM Darling (ref16) 2011; 53 EG Meissner (ref5) 2015; 35 A Osinusi (ref24) 2013; 310 M Zeremski (ref11) 2011; 55 A Riva (ref20) 2014; 60 M Zeremski (ref7) 2008; 48 S Beinhardt (ref17) 2012; 142 A Osinusi (ref25) 2014; 161 A Casrouge (ref19) 2011; 121 JR Larrubia (ref9) 2007; 47 B Martin (ref4) 2014; 61 AI Romero (ref15) 2006; 194 A Casrouge (ref18) 2012; 167 M Diago (ref13) 2006; 55 J Soderholm (ref22) 2013; 8 DM Rissin (ref23) 2010; 28 M Zeremski (ref10) 2007; 14 M Lagging (ref14) 2006; 44 D Ragab (ref21) 2013; 63 N Nguyen (ref12) 2014; 29 EG Meissner (ref3) 2014; 124 A Kohli (ref2) 2014; 312 J Brownell (ref8) 2013; 59 17875002 - J Viral Hepat. 2007 Oct;14(10):675-87 24905492 - J Hepatol. 2014 Sep;61(3):538-43 26418245 - PLoS One. 2015;10(9):e0139818 22132893 - Clin Exp Immunol. 2012 Jan;167(1):137-48 25117132 - JAMA. 2014 Aug 13;312(6):631-40 23664274 - Cytokine. 2013 Aug;63(2):105-12 21183794 - J Clin Invest. 2011 Jan;121(1):308-17 16150856 - Gut. 2006 Mar;55(3):374-9 24983321 - J Clin Invest. 2014 Aug;124(8):3352-63 21254158 - Hepatology. 2011 Jan;53(1):14-22 23982366 - JAMA. 2013 Aug 28;310(8):804-11 25013048 - Science. 2014 Jul 11;345(6193):141-2 23437290 - PLoS One. 2013;8(2):e56991 20495550 - Nat Biotechnol. 2010 Jun;28(6):595-9 22192885 - Gastroenterology. 2012 Jan;142(1):78-85.e2 24668726 - Hepatology. 2014 Aug;60(2):487-96 21256906 - J Hepatol. 2011 Sep;55(3):545-53 24373081 - Liver Int. 2014 Feb;34 Suppl 1:69-78 24236853 - J Gastroenterol Hepatol. 2014 Apr;29(4):860-9 17133471 - Hepatology. 2006 Dec;44(6):1617-25 25424883 - Liver Int. 2015 Feb;35(2):295-6 25364884 - Ann Intern Med. 2014 Nov 4;161(9):634-8 16960776 - J Infect Dis. 2006 Oct 1;194(7):895-903 17560677 - J Hepatol. 2007 Nov;47(5):632-41 18798334 - Hepatology. 2008 Nov;48(5):1440-50 23770038 - J Hepatol. 2013 Oct;59(4):701-8 |
| References_xml | – volume: 35 start-page: 295 issue: 2 year: 2015 ident: ref5 article-title: Continued value in understanding viral kinetic decline during interferon-free therapy for HCV publication-title: Liver international: official journal of the International Association for the Study of the Liver doi: 10.1111/liv.12748 – volume: 124 start-page: 3352 issue: 8 year: 2014 ident: ref3 article-title: Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome publication-title: J Clin Invest doi: 10.1172/JCI75938 – volume: 60 start-page: 487 issue: 2 year: 2014 ident: ref20 article-title: Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection publication-title: Hepatology doi: 10.1002/hep.27139 – volume: 34 start-page: 69 issue: Suppl 1 year: 2014 ident: ref1 article-title: HCV direct-acting antiviral agents: the best interferon-free combinations publication-title: Liver international: official journal of the International Association for the Study of the Liver doi: 10.1111/liv.12423 – volume: 167 start-page: 137 issue: 1 year: 2012 ident: ref18 article-title: Discrimination of agonist and antagonist forms of CXCL10 in biological samples publication-title: Clinical and experimental immunology doi: 10.1111/j.1365-2249.2011.04488.x – volume: 55 start-page: 545 issue: 3 year: 2011 ident: ref11 article-title: Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection publication-title: J Hepatol doi: 10.1016/j.jhep.2010.12.033 – volume: 161 start-page: 634 issue: 9 year: 2014 ident: ref25 article-title: Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse: An Open-Label Pilot Study publication-title: Ann Intern Med doi: 10.7326/M14-1211 – volume: 142 start-page: 78 issue: 1 year: 2012 ident: ref17 article-title: Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection publication-title: Gastroenterology doi: 10.1053/j.gastro.2011.09.039 – volume: 48 start-page: 1440 issue: 5 year: 2008 ident: ref7 article-title: Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C publication-title: Hepatology doi: 10.1002/hep.22500 – volume: 63 start-page: 105 issue: 2 year: 2013 ident: ref21 article-title: CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients publication-title: Cytokine doi: 10.1016/j.cyto.2013.04.016 – volume: 310 start-page: 804 issue: 8 year: 2013 ident: ref24 article-title: Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial publication-title: JAMA: the journal of the American Medical Association doi: 10.1001/jama.2013.109309 – volume: 53 start-page: 14 issue: 1 year: 2011 ident: ref16 article-title: Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response publication-title: Hepatology doi: 10.1002/hep.24056 – volume: 194 start-page: 895 issue: 7 year: 2006 ident: ref15 article-title: Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection publication-title: J Infect Dis doi: 10.1086/507307 – volume: 345 start-page: 141 issue: 6193 year: 2014 ident: ref6 article-title: Medicine. Hepatitis C can be cured globally, but at what cost? publication-title: Science doi: 10.1126/science.1257737 – volume: 44 start-page: 1617 issue: 6 year: 2006 ident: ref14 article-title: IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection publication-title: Hepatology doi: 10.1002/hep.21407 – volume: 59 start-page: 701 issue: 4 year: 2013 ident: ref8 article-title: Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes publication-title: J Hepatol doi: 10.1016/j.jhep.2013.06.001 – volume: 61 start-page: 538 issue: 3 year: 2014 ident: ref4 article-title: Restoration of HCV-specific CD8+ T cell function by interferon-free therapy publication-title: J Hepatol doi: 10.1016/j.jhep.2014.05.043 – volume: 47 start-page: 632 issue: 5 year: 2007 ident: ref9 article-title: The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection publication-title: J Hepatol doi: 10.1016/j.jhep.2007.04.009 – volume: 121 start-page: 308 issue: 1 year: 2011 ident: ref19 article-title: Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV publication-title: J Clin Invest doi: 10.1172/JCI40594 – volume: 29 start-page: 860 issue: 4 year: 2014 ident: ref12 article-title: Positioning of leukocyte subsets in the portal and lobular compartments of hepatitis C virus-infected liver correlates with local chemokine expression publication-title: Journal of gastroenterology and hepatology doi: 10.1111/jgh.12462 – volume: 28 start-page: 595 issue: 6 year: 2010 ident: ref23 article-title: Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations publication-title: Nat Biotechnol doi: 10.1038/nbt.1641 – volume: 55 start-page: 374 issue: 3 year: 2006 ident: ref13 article-title: Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C publication-title: Gut doi: 10.1136/gut.2005.074062 – volume: 14 start-page: 675 issue: 10 year: 2007 ident: ref10 article-title: The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2006.00838.x – volume: 8 start-page: e56991 issue: 2 year: 2013 ident: ref22 article-title: Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection publication-title: PLoS One doi: 10.1371/journal.pone.0056991 – volume: 312 start-page: 631 issue: 6 year: 2014 ident: ref2 article-title: Treatment of hepatitis C: a systematic review publication-title: JAMA: the journal of the American Medical Association doi: 10.1001/jama.2014.7085 – reference: 26418245 - PLoS One. 2015;10(9):e0139818 – reference: 24905492 - J Hepatol. 2014 Sep;61(3):538-43 – reference: 25013048 - Science. 2014 Jul 11;345(6193):141-2 – reference: 16150856 - Gut. 2006 Mar;55(3):374-9 – reference: 25117132 - JAMA. 2014 Aug 13;312(6):631-40 – reference: 22132893 - Clin Exp Immunol. 2012 Jan;167(1):137-48 – reference: 24373081 - Liver Int. 2014 Feb;34 Suppl 1:69-78 – reference: 21254158 - Hepatology. 2011 Jan;53(1):14-22 – reference: 23664274 - Cytokine. 2013 Aug;63(2):105-12 – reference: 17875002 - J Viral Hepat. 2007 Oct;14(10):675-87 – reference: 17560677 - J Hepatol. 2007 Nov;47(5):632-41 – reference: 20495550 - Nat Biotechnol. 2010 Jun;28(6):595-9 – reference: 25364884 - Ann Intern Med. 2014 Nov 4;161(9):634-8 – reference: 23437290 - PLoS One. 2013;8(2):e56991 – reference: 23982366 - JAMA. 2013 Aug 28;310(8):804-11 – reference: 22192885 - Gastroenterology. 2012 Jan;142(1):78-85.e2 – reference: 16960776 - J Infect Dis. 2006 Oct 1;194(7):895-903 – reference: 25424883 - Liver Int. 2015 Feb;35(2):295-6 – reference: 18798334 - Hepatology. 2008 Nov;48(5):1440-50 – reference: 17133471 - Hepatology. 2006 Dec;44(6):1617-25 – reference: 24668726 - Hepatology. 2014 Aug;60(2):487-96 – reference: 21256906 - J Hepatol. 2011 Sep;55(3):545-53 – reference: 23770038 - J Hepatol. 2013 Oct;59(4):701-8 – reference: 24983321 - J Clin Invest. 2014 Aug;124(8):3352-63 – reference: 24236853 - J Gastroenterol Hepatol. 2014 Apr;29(4):860-9 – reference: 21183794 - J Clin Invest. 2011 Jan;121(1):308-17 |
| SSID | ssj0053866 |
| Score | 2.316117 |
| Snippet | Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy.... |
| SourceID | plos doaj pubmedcentral hal proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0133236 |
| SubjectTerms | Adult Amino acids Analysis Antiviral Agents - therapeutic use Benzimidazoles - therapeutic use Biological response modifiers Biomarkers Care and treatment Chemokine CXCL10 - blood Chemokine CXCL10 - genetics Chemokines Chronic infection Clinical outcomes Convalescence Critical care CXCL10 protein Dendritic cells Dipeptidyl Peptidase 4 - blood Dipeptidyl Peptidase 4 - genetics Drug dosages Drug Therapy, Combination Female Fluorenes - therapeutic use Genotype & phenotype Genotypes Health aspects Hepacivirus - drug effects Hepacivirus - physiology Hepatitis Hepatitis C virus Hepatitis C, Chronic - blood Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - genetics Hepatitis C, Chronic - virology Hepatology Humans Immunology Infection Infections Infectious diseases Interferon Interferons Laboratories Life Sciences Liver diseases Male Post-translation Protein Processing, Post-Translational Proteins Recurrence Ribavirin Ribavirin - therapeutic use Serum levels Sofosbuvir - therapeutic use Statistical analysis Studies Therapy Treatment Outcome Viral Load - drug effects Virus Replication - drug effects |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9MwFLegJy6I8bWOAQYhPg7Zasdx3GPpqAraYIJt6i2yHZtWqpKqaZE484_znpOWBk0aB671qxK_z59fnt8j5JVV3mrNRdSXTEciVjJSfZFHsmdz05dJzEMRzdlnOb4UnybJZGfUF9aE1e2Ba8YdS-4SayHKpcwLC_rV87l3yiRaJhBbg_eFmLc5TNU-GKxYyuaiXJyy40YuR4uycEcAemIeWjL_CUShX__WK9-eYlFkZzEvq-uA59_1kzsBaXSP3G2QJB3UO9gjt1xxn-w1tlrRt01D6XcPyK-Teuw8ra8SVLT0FIf0RiFQzZt04PwnPSvzmQdMSkeAZAPZcDI8ZT2qi5xiAs3MHT05Pxd0VtDx8IqC28E8TkUBfboZ5iZoSDF6tyyLaLR0jl7UbQseksvRh4vhOGqGL0QWjH4VaZ0rl3BvnfRWKaedA-yQ8lxplxuwXGYNN6bPWWy4k8Y4zZwAMBA7xlMu4kekUwC79wlVOKJdGQPIzItUJzqXqelrAF_GWO5Vl8QbSWS26UyOAzLmWfjclsIJpWZphvLLGvl1SbT916LuzHED_XsU8pYW-2qHH0Dbskbbspu0rUueo4pk9SXVrXfIBoJjbob14i55GSiwt0aBxTvf9bqqso9frv6B6NvXFtGbhsiXwA6rmwsTsCfs2dWiPGxRgoewreXXU2TGzsbHg9NsocGPrJfIHwUHWfGDdck-6vyGfVXGsHWSSqRI4REbO7h--cV2GZ-OlXuFK9eBBjB4L0aax7XZbN8ETu8K8DooQNoyqNartleK2TT0QBcJViKIg_8h1CfkDsDgBDP2TB6Szmq5dk8Baq7Ms-BVfgMiPHsa priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELe28sILYnytY4BBiI-HVI3jOO4DQqWjKmiFCdapb5HtOGulKClJi9gz_zh3SRotqHy8xj8rztl3_vlyviPkuZGxUYpxZyBc5XBPCkcOeOSIvon0QPgeK4Nopp_EZMY_zv35HtnWbK0FWOw82mE9qVme9H58u3oLCv-mrNoQuNtOvVWW2h5QGo95Yp_cgL0pQFWd8ua_Ami3EPUFuj_1bG1QZR7_xlrvLzBYsrNKsmIXIf09rvLaRjW-TW7VDJMOqyVxQPZseocc1Dpc0Fd1ounXd8nPk6ocPa2uGBQ0iykW73XKDSyp3YTJFZ1m0TIGrkrHwHBL2Gg-OnX7VKURRceaTiw9OTvjdJnSyeiCgjlC_05BgZXaJfosaOl6jG2epc44t5aeV-kM7pHZ-P35aOLURRkcA8Zg7SgVSeuz2FgRGymtshY4RcAiqWykQaNdo5nWA-Z6mlmhtVWu5UASPOuygHHvPumkIO5DQiWWbpdaA2OLeaB8FYlADxSQMq0Ni2WXeNuZCE2dsRwLZyRh-RsugJNLJdIQ5y-s569LnKbXqsrY8Q_8O5zkBov5tssHWX4Z1uobCmZ9Y4BrBW7MDVi5fhzFVmpfCR8YHuuSJ7hEwuryamM1wiFn6LNx-16XPCsRmHMjxaCeS7UpivDD54v_AH390gK9rEFxBuIwqr5IAd-EubxayOMWEiyHaTW_WKAwrn34ZHgarhTYl02O8pFwwOXf3S45xDW_FV8RuphSSfqCB_CKrR7sbn7aNOPbMaIvtdmmxAA373uIeVCpTTMSONVL4PGwAIKWQrWG2m5Jl4syNzr3MUKBH_19WA_JTSC-PvroXXFMOut8Yx8BuVzrx6W9-AU2rnie priority: 102 providerName: Scholars Portal |
| Title | Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26181438 https://www.proquest.com/docview/1696885647 https://www.proquest.com/docview/1698390347 https://pasteur.hal.science/pasteur-01380964 https://pubmed.ncbi.nlm.nih.gov/PMC4504464 https://doaj.org/article/62e5cc31771f4c5780fdfe8b5a659932 http://dx.doi.org/10.1371/journal.pone.0133236 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dT9swELcGvOxlGvuijDFvmvbxEGgcx3GfJih03QQMMUB9i2zHoZWqpGvopD3vH9-d4wYyoW0vfqivinP2nX--nH9HyBsjc6MU40FPhCrgkRSB7PEsEF2T6Z6II-aSaI5PxPCCfxnFIx9wq3xa5dInOkedlQZj5LshsrjIWPDk4-x7gFWj8OuqL6GxQtaQugxTupJRc-ACWxbCX5eLknDXz87OrCzsDkCfiDli5pvtyLH2N755ZYypkauzaVndBT__zKK8tS0NHpIHHk_SvXoBrJN7tnhE1r3FVvS9p5X-8Jj8OqiLz9P6QkFFy5xiqd7AbVdTHxSc_qTHZTbJAZnSAeBZJ9Yf9Y_CLlVFRjGMpqeWHpyecjop6LB_ScH5YDSnooBB7QQjFNQFGnM7L4tgMLeWntfkBU_IxeDwvD8MfAmGwIDpXwdKZdLGLDdW5EZKq6wFBJGwTCqbabDf0GimdY-FkWZWaG1VaDlAgsiGLGE8ekpWC1D3BqESC7VLrQGf5TxRscpEonsKIJjWhuWyQ6LlTKTG85NjmYxp6j66JXBOqVWa4vylfv46JGj-Nav5Of4hv4-T3Mgiu7b7oZxfpd5YU8FsbAwgqyTMuQGf1s2z3EodKxEDnmMd8hKXSFpfVW18RLrHGUZowm7UIa-dBDJsFJjCc6UWVZV-_nr5H0LfzlpC77xQXoI6jPLXJuCdkLmrJbnVkgQ_YVrdb8eojFsvPtw7SmcKvMlijvqRcJzlP8IO2cA1v1Rfld6YHjxiaQd3d79quvHpmL9X2HLhZACJdyOUeVabTTMSOMNLQO2wAJKWQbWG2u4pJmPHhM5jzEfgm38f1nNyH2BujBH5UGyR1ev5wr4AKHmtt52_gFb2Q2wHn7bJ2v7hyenZtgvOQHvM5W-K7ngD |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lc9MwENa05QAXhvJqoFDB8Dy4jWVZVg4MU1IyKU1Lhz4mNyPJcpuZjB3iBqZn_g-_kV3ZcWumA1x6jdaxLK2-_bRa7RLywsjUKMW41xG-8ngghSc7PPFE2yS6I8KAuSCa3T3RP-KfhuFwgfya34XBsMo5JjqgTnKDPvINH7O4yFDw6P3km4dVo_B0dV5Co1SLHXv-A7ZsxbvtLZjfl4z1Ph52-15VVcAzoM1nnlKJtCFLjRWpkdIqa8EoRiyRyiYaVNI3mmndYX6gmRVaW-VbDlYusD6LGA_gfxfJDTC8bVxR0bDe4AF2CFFdzwsif6PShvVJntl1oFoBc4mgL8yfqxJQ24LFUwzFXJqM8-Iquvtn1OYlM9i7Q25X_JVulgq3TBZsdpcsVwhR0DdVGuu398jPrbLYPS0vMBQ0TymWBvaceRxXTsjxOd3Nk1EKTJj2gD87se6wO_DbVGUJRbedHlu6tb_P6Sij_e4xBbBD71FBgfPaEXpEqHNspnaaZ15vai09LJMl3CdH1zI5D8hSBsO9QqjEwvBSa-CDKY9UqBIR6Y4Cyqe1YalskWA-E7Gp8qFjWY5x7A75ItgXlUMa4_zF1fy1iFc_NSnzgfxD_gNOci2L2bzdD_n0JK7AIRbMhsYAk4v8lBvA0HaapFbqUIkQ-CNrkTVUkbi8GltjUrzJGXqE_HbQIs-dBGb0yDBk6ETNiiLe_nz8H0IHXxpCryuhNIfhMKq6pgHfhJnCGpKrDUnAJdNofnWKg3Hpw_ubg3iiAL1mUxwfCdtn_t1vkRXU-fnwFfHFUodXzNfB1c3P6mZ8O8YLZjafORlg_u0AZR6Wy6buCRPAagGVWiRqLKhGV5st2ejUZV7nIcY_8Ed_79Yaudk_3B3Eg-29ncfkFlDsEE8DfLFKls6mM_sEaOyZfuqwg5Kv1w1WvwEbbLGK |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe2ISFeEONrhcEM4vMhW-04TvqA0GipOvbBxD7Ut2A7zlapSkqzgvbMf8Vfx13iZguagJe91pfG8Z1__vl8viPkhYlSoxQXXkcy5Qk_kl7UEYkn2ybRHRn4vAyi2d2TgyPxaRgMF8iv-V0YDKucY2IJ1Elu0Ee-wTCLSxRIEW6kLixiv9d_P_nmYQUpPGmdl9OoTGTbnv-A7VvxbqsHun7Jef_jYXfguQoDngHLPvOUSiIb8NRYmZoosspaWCBDnkTKJhrMkxnNte5w5mtupdZWMStgxfMt4yEXPvzvIrkR-gHDORYO680e4IiU7qqeH7INZxnrkzyz60C7fF4mhb5YCsuKAfW6sHiKYZlLk3FeXEV9_4zgvLQk9u-Q247L0s3K-JbJgs3ukmWHFgV941Jav71Hfvaqwve0usxQ0DylWCbYK5fKsXNIjs_pbp6MUmDFtA9cuhTrDrs7rE1VllB04emxpb39fUFHGR10jykAH3qSCgr8147QO0JLJ2dqp3nm9afW0sMqccJ9cnQtynlAljIY7hVCIywSH2kN3DAVoQpUIkPdUUD_tDY8jVrEn2siNi43OpboGMflgV8Ie6RqSGPUX-z01yJe_dSkyg3yD_kPqORaFjN7lz_k05PYAUUsuQ2MAVYXslQYwNN2mqQ20oGSAXBJ3iJraCJxdU22xqd4U3D0DrG23yLPSwnM7pHhPDlRs6KItz4f_4fQwZeG0GsnlOYwHEa5KxvwTZg1rCG52pAEjDKN5lenOBiXPnywuRNPFCDZbIrjE8FWWnxnLbKCNj8fviK-mPbwivk8uLr5Wd2Mb8fYwczms1IGdgFtH2UeVtOm7gmXwHABoVokbEyoRlebLdnotMzCLgKMhRCP_t6tNXITYCre2drbfkxuAdsO8GCAyVWydDad2SfAaM_00xI6KPl63Vj1G3YhtcA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dynamic+Changes+of+Post-Translationally+Modified+Forms+of+CXCL10+and+Soluble+DPP4+in+HCV+Subjects+Receiving+Interferon-Free+Therapy&rft.jtitle=PloS+one&rft.au=Meissner%2C+Eric+G&rft.au=Decalf%2C+J%C3%A9r%C3%A9mie&rft.au=Casrouge%2C+Armanda&rft.au=Masur%2C+Henry&rft.date=2015-07-16&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=10&rft.issue=7&rft.spage=e0133236&rft_id=info:doi/10.1371%2Fjournal.pone.0133236&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=3745590091 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |